Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels


MiMedx Group, Inc. (Nasdaq: MDXG) (MiMedx or the Company), an industry leader in advanced wound care and a therapeutic biologics company, today announced that management will be participating in the following virtual investor conferences:


GlobeNewswire Inc | Mar 3, 2021 08:00AM EST

March 03, 2021

MARIETTA, Ga., March 03, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (MiMedx or the Company), an industry leader in advanced wound care and a therapeutic biologics company, today announced that management will be participating in the following virtual investor conferences:

-- H.C. Wainwright Global Life Sciences ConferencePresentation: Wednesday, March 10, 2021 available to view on-demand beginning at 2:00 PM ET through the entirety of the conferenceManagement Participants: Timothy R. Wright, Chief Executive Officer, and Peter M. Carlson, Chief Financial OfficerWebcast: Click here to access

-- Oppenheimer 31st Annual Healthcare ConferenceFireside Chat: Tuesday, March 16, 2021 at 3:50 PM ETManagement Participants: Timothy R. Wright and Robert B. Stein, M.D., Ph.D., Executive Vice President, Research and DevelopmentWebcast:Click here to access

Institutional investors interested in meeting with management at the above conferences may contact their respective H.C. Wainwright or Oppenheimer representative.

A live webcast of both presentations will be available on the Events page of the Investors section of the Companys website at www.mimedx.com or through the conference site by using the links above. A replay will be available on the Companys website following the event.

About MiMedxMiMedx is an industry leader in advanced wound care and a therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The Company processes the human placental tissue utilizing its proprietary PURION process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx has supplied more than two million allografts, through both direct and consignment shipments. For additional information, please visitwww.mimedx.com.

Contacts:InvestorsJack Howarth404-360-5681investorrelations@mimedx.com







Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC